SCHEMBL5110141

SCHEMBL5110141

CCCc1cncc(CO)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.42
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
AR P10275 1/20 0.35
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
S1PR1 P21453 1/20 0.34
TKT P29401 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16390248 0.89 NOS1 (0.42) CHRNB2CHRNA4NOS1NOS2CNR1
SCHEMBL4542065 0.86 TDP1 (0.50) CYP2A6TDP1L3MBTL1
SCHEMBL2728918 0.83 CYP2A6 (0.47) CYP2A6CYP11B1CYP11B2ARPRMT5
SCHEMBL13534018 0.82 NOS1 (0.39) CHRNB2CHRNA4NOS1NOS2CNR1
SCHEMBL844561 0.82 CYP2A6 (0.44) CYP2A6CYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL9220960 0.79 ACHE (0.43) CNR1CNR2
SCHEMBL16942780 0.78 PTGS2 (0.42) CYP11B1CYP11B2CHRNB2CHRNA4CNR1
Acetic Acid SCHEMBL6983638 0.76 CYP2A6 (0.43) CYP2A6CYP11B1CYP11B2AR
SCHEMBL4289948 0.76 TKT (0.44) CYP11B1CYP11B2CHRNB2CHRNA4NOS1
SCHEMBL24081239 0.75 DHFR (0.36) CHRNB2CHRNA4NOS1NOS2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors PHARMASUM THERAPEUTICS AS (NO) 2021-02-23 US disclosed
US-7342116-B2 Process for producing heterocyclic aldehyde KOEI CHEMICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20050124807-A1 oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound KOEI CHEMICAL CO., LTD. (JP) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors DYRK1A, DYRK1B, PDK2 CYP2A6 2279/4885CYP11B1 756/4885CYP11B2 1118/4885
US-20050124807-A1 oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound ADH1C, ADH1A, AOX1 CYP2A6 69/4885CYP11B1 80/4885CYP11B2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.